Local immune response as novel disease mechanism underlying abdominal pain in patients with irritable bowel syndrome

ABSTRACT Objectives Irritable bowel syndrome (IBS) is the most frequently diagnosed functional gastrointestinal disorder, with a prevalence of up to 25% of the global population. IBS patients suffer from abnormal abdominal pain, or visceral hypersensitivity (VHS), associated with altered bowel habits in the absence of an organic detectable cause. The pathophysiology of the disease is incompletely understood, but the dysregulation of the brain-gut axis is well established in IBS. Methods IBS onset is mainly triggered by infectious gastroenteritis, psychological factors, and dietary factors, but genetic predispositions and intestinal dysbiosis might also play a role. Additionally, immune activation, and particularly chronic mast cell activation, have been shown to underlie the development of abdominal pain in IBS. Results By releasing increased levels of mediators, including histamine, mast cells sensitize enteric nociceptors and lead to VHS development. The mechanisms underlying aberrant mast cell activation in IBS are still under investigation, but we recently showed that a local break in oral tolerance to food antigens led to IgE-mediated mast cell activation and food-induced abdominal pain in preclinical models and in IBS patients. Conclusion The concept of food-mediated VHS highlights the potential of therapies targeting upstream mechanisms of mast cell sensitization to treat IBS.

[1]  M. Camilleri.  Diagnosis and Treatment of Irritable Bowel Syndrome: A Review. , 2021, JAMA.

[2]  J. Raes,et al.  Local immune response to food antigens drives meal-induced abdominal pain , 2021, Nature.

[3]  J. Raes,et al.  Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome with Predominant Abdominal Bloating: Short- and Long-Term Results from a Placebo-Controlled Randomized Trial. , 2020, Gastroenterology.

[4]  Mimi Y. Kim,et al.  Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. , 2019, The lancet. Gastroenterology & hepatology.

[5]  D. Lambrechts,et al.  Expression of immune‐related genes in rectum and colon descendens of Irritable Bowel Syndrome patients is unrelated to clinical symptoms , 2019, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[6]  P. Higgins,et al.  Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. , 2019, The American journal of gastroenterology.

[7]  G. Boeckxstaens,et al.  Histamine-mediated potentiation of transient receptor potential (TRP) ankyrin 1 and TRP vanilloid 4 signaling in submucosal neurons in patients with irritable bowel syndrome. , 2019, American journal of physiology. Gastrointestinal and liver physiology.

[8]  S. Brierley,et al.  Visceral Pain. , 2019, Annual review of physiology.

[9]  W. Chey.  Elimination Diets for Irritable Bowel Syndrome: Approaching the End of the Beginning. , 2019, The American journal of gastroenterology.

[10]  U. Ghoshal,et al.  Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. , 2019, Gastroenterology.

[11]  W. Whitehead,et al.  Systemic cytokines are elevated in a subset of patients with irritable bowel syndrome but largely unrelated to symptom characteristics , 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[12]  L. Hansen,et al.  Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study , 2018, Gut.

[13]  D. Iliopoulos,et al.  Sigmoid colon mucosal gene expression supports alterations of neuronal signaling in irritable bowel syndrome with constipation. , 2018, American journal of physiology. Gastrointestinal and liver physiology.

[14]  F. Redegeld,et al.  Non‐IgE mediated mast cell activation , 2018, Immunological reviews.

[15]  G. Boeckxstaens,et al.  Evidence for long-term sensitization of the bowel in patients with post-infectious-IBS , 2017, Scientific Reports.

[16]  W. D. de Jonge,et al.  Intestinal Fungal Dysbiosis Is Associated With Visceral Hypersensitivity in Patients With Irritable Bowel Syndrome and Rats. , 2017, Gastroenterology.

[17]  G. Latella,et al.  Low-FODMAP Diet Improves Irritable Bowel Syndrome Symptoms: A Meta-Analysis , 2017, Nutrients.

[18]  R. Xavier,et al.  Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease , 2017, Science.

[19]  M. Camilleri,et al.  Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. , 2017, Gastroenterology.

[20]  L. Öhman,et al.  Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome , 2016, The American Journal of Gastroenterology.

[21]  P. Carmeliet,et al.  Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. , 2016, Gastroenterology.

[22]  M. D’Amato,et al.  Genetics of irritable bowel syndrome , 2016, Molecular and Cellular Pediatrics.

[23]  L. Böhn,et al.  Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. , 2015, Gastroenterology.

[24]  R. Spiller,et al.  Irritable bowel syndrome , 2015, Nature Reviews Disease Primers.

[25]  A. Carroccio,et al.  Food allergy in irritable bowel syndrome: The case of non-celiac wheat sensitivity. , 2015, World journal of gastroenterology.

[26]  P. Gibson,et al.  Review article: gut‐directed hypnotherapy in the management of irritable bowel syndrome and inflammatory bowel disease , 2015, Alimentary pharmacology & therapeutics.

[27]  P. Gibson,et al.  Food components and irritable bowel syndrome. , 2015, Gastroenterology.

[28]  C. Bachert,et al.  Local Immunoglobulin E in the Nasal Mucosa: Clinical Implications , 2015, Allergy, asthma & immunology research.

[29]  Mark Ellrichmann,et al.  Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. , 2014, Gastroenterology.

[30]  E. Halmos,et al.  The role of FODMAPs in irritable bowel syndrome , 2014, Current opinion in clinical nutrition and metabolic care.

[31]  Xinzhong Dong,et al.  Identification of a mast cell specific receptor crucial for pseudo-allergic drug reactions , 2014, Nature.

[32]  C. Pucillo,et al.  Mast cell activation: A complex interplay of positive and negative signaling pathways , 2014, European journal of immunology.

[33]  D. R. Linden,et al.  Neuroplasticity and dysfunction after gastrointestinal inflammation , 2014, Nature Reviews Gastroenterology &Hepatology.

[34]  G. Boeckxstaens,et al.  Sensitivity Testing in Irritable Bowel Syndrome With Rectal Capsaicin Stimulations: Role of TRPV1 Upregulation and Sensitization in Visceral Hypersensitivity? , 2014, The American Journal of Gastroenterology.

[35]  J. Tack,et al.  Interaction between preprandial and postprandial rectal sensory and motor abnormalities in IBS , 2013, Gut.

[36]  P. Whorwell,et al.  Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome , 2013, Gut.

[37]  A. Kraneveld,et al.  New Perspective on Dextran Sodium Sulfate Colitis: Antigen-Specific T Cell Development during Intestinal Inflammation , 2013, PloS one.

[38]  G. Boeckxstaens,et al.  Stress-Induced Visceral Hypersensitivity in Maternally Separated Rats Can Be Reversed by Peripherally Restricted Histamine-1-Receptor Antagonists , 2013, PloS one.

[39]  L. Böhn,et al.  Self-Reported Food-Related Gastrointestinal Symptoms in IBS Are Common and Associated With More Severe Symptoms and Reduced Quality of Life , 2013, The American Journal of Gastroenterology.

[40]  A. Ford,et al.  Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[41]  K. Ravid,et al.  Mast Cell Adenosine Receptors Function: A Focus on the A3 Adenosine Receptor and Inflammation , 2012, Front. Immun..

[42]  D. Dumitrascu,et al.  Psychosocial determinants of irritable bowel syndrome. , 2012, World journal of gastroenterology.

[43]  C. Wilder-Smith.  The balancing act: endogenous modulation of pain in functional gastrointestinal disorders , 2011, Gut.

[44]  Sigrid Elsenbruch,et al.  Abdominal pain in Irritable Bowel Syndrome: A review of putative psychological, neural and neuro-immune mechanisms , 2011, Brain, Behavior, and Immunity.

[45]  K. Alysandratos,et al.  Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells , 2011, The Journal of investigative dermatology.

[46]  B. Greenwood-Van Meerveld,et al.  A novel TRPV1 receptor antagonist JNJ-17203212 attenuates colonic hypersensitivity in rats. , 2010, Methods and findings in experimental and clinical pharmacology.

[47]  G. Boeckxstaens,et al.  The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome , 2010, Gut.

[48]  A. Sperber,et al.  Irritable Bowel Syndrome and Co-morbid Gastrointestinal and Extra-gastrointestinal Functional Syndromes , 2010, Journal of neurogastroenterology and motility.

[49]  B. Fridley,et al.  Familial Aggregation of Irritable Bowel Syndrome: A Family Case–Control Study , 2010, The American Journal of Gastroenterology.

[50]  P. Moayyedi,et al.  Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[51]  David Julius,et al.  Cellular and Molecular Mechanisms of Pain , 2009, Cell.

[52]  M. Forsting,et al.  Affective disturbances modulate the neural processing of visceral pain stimuli in irritable bowel syndrome: an fMRI study , 2009, Gut.

[53]  C. Altier,et al.  Transient receptor potential vanilloid-4 has a major role in visceral hypersensitivity symptoms. , 2008, Gastroenterology.

[54]  A. Masclee,et al.  Symptom severity but not psychopathology predicts visceral hypersensitivity in irritable bowel syndrome. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[55]  Susan M. Schlenner,et al.  Molecular mechanism of mast cell–mediated innate defense against endothelin and snake venom sarafotoxin , 2007, The Journal of experimental medicine.

[56]  Jan Tack,et al.  Altered rectal perception in irritable bowel syndrome is associated with symptom severity. , 2007, Gastroenterology.

[57]  R. Spiller.  Role of infection in irritable bowel syndrome , 2007, Journal of Gastroenterology.

[58]  M. Vatn,et al.  Irritable bowel syndrome in twins: genes and environment , 2006, Gut.

[59]  F. Mearin,et al.  Bowel Habit Subtypes and Temporal Patterns in Irritable Bowel Syndrome: Systematic Review , 2005, The American Journal of Gastroenterology.

[60]  W. Whitehead,et al.  Patients and Nonconsulters with Irritable Bowel Syndrome Reporting a Parental History of Bowel Problems Have More Impaired Psychological Distress , 2004, Digestive Diseases and Sciences.

[61]  D. Santini,et al.  Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. , 2004, Gastroenterology.

[62]  R. Spiller,et al.  Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. , 2003, Gastroenterology.

[63]  Shara I. Feld,et al.  Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. , 2001, Gastroenterology.

[64]  W. Fokkens,et al.  Local production and detection of (specific) IgE in nasal B-cells and plasma cells of allergic rhinitis patients. , 2000, The European respiratory journal.

[65]  M. Manns,et al.  Colonoscopic allergen provocation (COLAP): a new diagnostic approach for gastrointestinal food allergy. , 1997, Gut.

[66]  E A Mayer,et al.  Altered rectal perception is a biological marker of patients with irritable bowel syndrome. , 1995, Gastroenterology.

[67]  J. Munakata,et al.  Evidence for the hypersensitivity of lumbar splanchnic afferents in irritable bowel syndrome. , 1994, Gastroenterology.

[68]  G. Sturniolo,et al.  [Irritable bowel syndrome]. , 1988, Giornale di clinica medica.

[69]  J. Ritchie.  Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome 1 , 1973, Gut.

[70]  P. Valle,et al.  Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. , 2018, The lancet. Gastroenterology & hepatology.

[71]  Luca Marciani,et al.  Colon Hypersensitivity to Distension, Rather Than Excessive Gas Production, Produces Carbohydrate-Related Symptoms in Individuals With Irritable Bowel Syndrome. , 2017, Gastroenterology.

[72]  R. Spiller,et al.  Bowel Disorders. , 2016, Gastroenterology.

[73]  O. I. Stanisor.  Pathophysiology of stress-induced visceral hypersensitivity , 2014 .

[74]  A. Patapoutian,et al.  Transient receptor potential channels: targeting pain at the source , 2009, Nature Reviews Drug Discovery.

[75]  A. Zinsmeister,et al.  FUNCTIONAL BOWEL DISORDERS , 2007, The American Journal of Gastroenterology.

[76]  M. Manns,et al.  Clinical significance of the colonoscopic allergen provocation test. , 1997, International archives of allergy and immunology.